Sort by
Items per page

Send to

Choose Destination

Best matches for Immunotherapy for synovial sarcoma:

Synovial Sarcoma: Current Concepts and Future Perspectives. Stacchiotti S et al. J Clin Oncol. (2018)

The future of immunotherapy for sarcoma. Tsukahara T et al. Expert Opin Biol Ther. (2016)

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. Robbins PF et al. J Clin Oncol. (2011)

Search results

Items: 1 to 20 of 106


Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial.

Zhang S, Kohli K, Black RG, Yao L, Spadinger SM, He Q, Pillarisetty VG, Cranmer LD, Van Tine BA, Yee C, Pierce RH, Riddell SR, Jones RL, Pollack SM.

Cancer Immunol Res. 2019 Aug;7(8):1237-1243. doi: 10.1158/2326-6066.CIR-18-0940. Epub 2019 Jun 6.


Expression of New York esophageal squamous cell carcinoma 1 and its association with Foxp3 and indoleamine-2,3-dioxygenase in microenvironment of nonsmall cell lung cancer.

Wang H, Xia Y, Yu J, Guan H, Wu Z, Ban D, Wang M.

HLA. 2019 Jul;94(1):39-48. doi: 10.1111/tan.13547. Epub 2019 Apr 30.


Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma.

Kakimoto T, Matsumine A, Kageyama S, Asanuma K, Matsubara T, Nakamura T, Iino T, Ikeda H, Shiku H, Sudo A.

Oncol Lett. 2019 Apr;17(4):3937-3943. doi: 10.3892/ol.2019.10044. Epub 2019 Feb 14.


Standard treatment and emerging drugs for managing synovial sarcoma: adult's and pediatric oncologist perspective.

Baldi GG, Orbach D, Bertulli R, Magni C, Sironi G, Casanova M, Ferrari A.

Expert Opin Emerg Drugs. 2019 Mar;24(1):43-53. doi: 10.1080/14728214.2019.1591367. Review.


Analysis of mutations in primary and metastatic synovial sarcoma.

Xing Z, Wei L, Jiang X, Conroy J, Glenn S, Bshara W, Yu T, Pao A, Tanaka S, Kawai A, Choi C, Wang J, Liu S, Morrison C, Yu YE.

Oncotarget. 2018 Dec 7;9(96):36878-36888. doi: 10.18632/oncotarget.26416. eCollection 2018 Dec 7.


Next frontiers in systemic therapy for soft tissue sarcoma.

Yen CC, Chen TW.

Chin Clin Oncol. 2018 Aug;7(4):43. doi: 10.21037/cco.2018.08.04. Review.


Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens.

Wedekind MF, Haworth KB, Arnold M, Stanek JR, Lee D, Cripe TP.

Pediatr Blood Cancer. 2018 Nov;65(11):e27313. doi: 10.1002/pbc.27313. Epub 2018 Jul 17.


α-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10.

Li HK, Sugyo A, Tsuji AB, Morokoshi Y, Minegishi K, Nagatsu K, Kanda H, Harada Y, Nagayama S, Katagiri T, Nakamura Y, Higashi T, Hasegawa S.

Cancer Sci. 2018 Jul;109(7):2302-2309. doi: 10.1111/cas.13636. Epub 2018 Jun 27.


Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma.

D'Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, Grupp S, Tap WD, Chagin K, Binder GK, Basu S, Lowther DE, Wang R, Bath N, Tipping A, Betts G, Ramachandran I, Navenot JM, Zhang H, Wells DK, Van Winkle E, Kari G, Trivedi T, Holdich T, Pandite L, Amado R, Mackall CL.

Cancer Discov. 2018 Aug;8(8):944-957. doi: 10.1158/2159-8290.CD-17-1417. Epub 2018 Jun 11.


A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients.

Giraudet AL, Cassier PA, Iwao-Fukukawa C, Garin G, Badel JN, Kryza D, Chabaud S, Gilles-Afchain L, Clapisson G, Desuzinges C, Sarrut D, Halty A, Italiano A, Mori M, Tsunoda T, Katagiri T, Nakamura Y, Alberti L, Cropet C, Baconnier S, Berge-Montamat S, Pérol D, Blay JY.

BMC Cancer. 2018 Jun 8;18(1):646. doi: 10.1186/s12885-018-4544-x.


Human Leukocyte Antigen-A Allele Distribution in Nasopharyngeal Carcinoma Patients Showing Anti-Melanoma-Associated Antigen A or Synovial Sarcoma X-2 T Cell Response in Blood.

Fan PW, Huang L, Chang XM, Feng YN, Yao X, Peng YC, Dong T, Wang RZ.

Chin Med J (Engl). 2018 Jun 5;131(11):1289-1295. doi: 10.4103/0366-6999.232791.


A review of soft-tissue sarcomas: translation of biological advances into treatment measures.

Hoang NT, Acevedo LA, Mann MJ, Tolani B.

Cancer Manag Res. 2018 May 10;10:1089-1114. doi: 10.2147/CMAR.S159641. eCollection 2018. Review.


Primary renal synovial sarcoma: A case report and literature review.

Huang Y, Liu D, Luo J, Chen W.

J Cancer Res Ther. 2018;14(Supplement):S267-S269. doi: 10.4103/0973-1482.181170. Review.


Systemic Treatment for Adults with Synovial Sarcoma.

Desar IME, Fleuren EDG, van der Graaf WTA.

Curr Treat Options Oncol. 2018 Mar 7;19(2):13. doi: 10.1007/s11864-018-0525-1. Review.


[Cancer immunotherapy using gene-engineered T cells].

Kageyama S.

Rinsho Ketsueki. 2018;59(2):216-224. doi: 10.11406/rinketsu.59.216. Japanese.


PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.

Zheng B, Ren T, Huang Y, Sun K, Wang S, Bao X, Liu K, Guo W.

J Hematol Oncol. 2018 Feb 6;11(1):16. doi: 10.1186/s13045-018-0560-1. Erratum in: J Hematol Oncol. 2018 Mar 12;11(1):37.


PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy.

Boxberg M, Steiger K, Lenze U, Rechl H, von Eisenhart-Rothe R, Wörtler K, Weichert W, Langer R, Specht K.

Oncoimmunology. 2017 Nov 20;7(3):e1389366. doi: 10.1080/2162402X.2017.1389366. eCollection 2018.


The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.

Pollack SM.

Expert Rev Vaccines. 2018 Feb;17(2):107-114. doi: 10.1080/14760584.2018.1419068. Epub 2017 Dec 27. Review.


Synovial Sarcoma: Current Concepts and Future Perspectives.

Stacchiotti S, Van Tine BA.

J Clin Oncol. 2018 Jan 10;36(2):180-187. doi: 10.1200/JCO.2017.75.1941. Epub 2017 Dec 8. Review.


First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.

Pollack SM, Lu H, Gnjatic S, Somaiah N, O'Malley RB, Jones RL, Hsu FJ, Ter Meulen J.

J Immunother. 2017 Oct;40(8):302-306. doi: 10.1097/CJI.0000000000000183.

Supplemental Content

Loading ...
Support Center